Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Marshall Edwards -- MSHL

11 May 2005 12:31 PM <--

Return to Marshall Edwards -- MSHL

Marshall Edwards is a spin out of Novogen. While I'm wary of spinouts (we all remember the various Genzyme babies), MSHL's mission is to develop phenoxodiol, a very interesting cancer drug. An isoflavone analog derived by standard synthetic chemistry from genistein, it has shown early promise. With a small float, MSHL is not very liquid, and sometimes violent.

This thread is for polite discussion of MSHL, it parent, and its competitors.

Tuck